KRAS and pancreatic ductal adenocarcinoma: Focusing on KRAS G12D, GFH375 (VS-7375) has received fast track designation (FTD) for first-line treatment of patients with KRAS G12D mutation-positive locally advanced or metastatic pancreatic ductal adenocarcinoma, but is currently in phase I/II clinical study (NCT06500676) [343].